A Global Health Alert on the Re-Emergence of Mpox a Viral Zoonotic Illness Its Prevention and Management: A Narrative Review.

Background and Aims: Monkeypox virus (MPXV) is gaining attention in the global health community due to its potential for human transmission and similarities to the well-known smallpox virus. Mpox was first detected in the 1970s and mostly affects Central and West Africa. However, it has caused rare outbreaks in isolated regions worldwide, indicating a possible global health impact. Methodology: In this review, we will look at several elements of mpox, such as its epidemiological patterns, clinical symptoms in infected individuals, and contemporary diagnostic and preventative techniques. A large portion of this review is also devoted to assessing the efficacy and safety of investigational antiviral medicines like cidofovir and brincidofovir. These assessments are based on controlled experiments conducted in laboratory settings and investigations on animal models. Results: So far, the medical profession lacks antiviral drugs, particularly intended to combat mpox. However, research has yielded promising outcomes in the usage of investigational medications such as cidofovir and brincidofovir. In the absence of targeted antiviral therapies, mpox is primarily managed by supportive care. This involves attempts to alleviate symptoms, keep hydration and electrolyte balance, and adopt effective infection control techniques. Conclusion: This review provides an informative and thorough examination of mpox, emphasizing its importance and possible hazards in both public health and therapeutic settings. The lack of specialized antiviral therapies for mpox is a huge gap in our medical arsenal. However, continuous research into new medications provides a glimpse of optimism.